首页 >
法规速递
-
Document: Breakthrough status request: Template for applicants for breakthrough medical devices pilot-2026/4/28
2026-04-29查看详情 > -
关于公开征求《肿瘤治疗性疫苗临床试验技术指导原则（征求意见稿）》意见的通知-2022/10-9
2022-11-14查看详情 > -
国家药监局药审中心关于发布《儿童抗肿瘤药物临床研发技术指导原则》的通告（2023年第22号）-2023/03/24
2023-03-24查看详情 > -
国家药监局药审中心关于发布《多发性硬化治疗药物临床试验技术指导原则》的通告（2023年第49号-2023/9/28
2023-10-07查看详情 > -
Document: Mysimba Article-20 procedure - Timetable for the procedure-2025/1/6
2025-01-07查看详情 > -
Document: Overview of comments received on `Nilotinib hard capsules 50, 150 and 200 mg product-specific bioequivalence guidance’ (EMA/CHMP/518671/2023)-2025/2/12
2025-02-13查看详情 > -
关于公开征求ICH《E6（R3）：药物临床试验质量管理规范技术指导原则（GCP）》原则及附件1中文翻译稿意见的通知-2025/3/20
2025-03-21查看详情 > -
Document: Business process description for referral procedures-2025/4/22
2025-04-23查看详情 > -
Page: Quality of medicines questions and answers: Part 2-2025/6/3
2025-06-04查看详情 > -
Document: Guide to CTIS training material catalogue-2025/7/9
2025-07-10查看详情 >
